Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Wide step width reduces knee abduction moment of obese adults during stair negotiation.

Yocum D, Weinhandl JT, Fairbrother JT, Zhang S.

J Biomech. 2018 Jun 25;75:138-146. doi: 10.1016/j.jbiomech.2018.05.002.

PMID:
29776821
2.
3.

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW.

Sci Transl Med. 2011 Sep 21;3(101):101ra92. doi: 10.1126/scitranslmed.3002432.

4.
5.

Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients.

Flint-Wagner HG, Lisse J, Lohman TG, Going SB, Guido T, Cussler E, Gates D, Yocum DE.

J Clin Rheumatol. 2009 Jun;15(4):165-71. doi: 10.1097/RHU.0b013e318190f95f.

PMID:
19279507
6.

Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice.

Olech E, Freeston JE, Conaghan PG, Hensor EM, Emery P, Yocum D.

J Rheumatol. 2008 Apr;35(4):580-3. Epub 2008 Mar 1.

PMID:
18322995
7.

A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritis.

Huffstutter J, Craig WD, Schimizzi G, Harshbarger J, Lisse J, Kasle S, Hymson L, Yocum D, Castro L, Hegedus R, Callegari P, Yeilding N, Gilmer K.

Curr Med Res Opin. 2007 Aug;23(8):1967-79.

PMID:
17626700
8.

A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view.

Freeston JE, Olech E, Yocum D, Hensor EM, Emery P, Conaghan PG.

Ann Rheum Dis. 2007 Dec;66(12):1669-71. Epub 2007 Jul 6.

9.

Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.

Woodworth T, Furst DE, Alten R, Bingham CO 3rd, Yocum D, Sloan V, Tsuji W, Stevens R, Fries J, Witter J, Johnson K, Lassere M, Brooks P.

J Rheumatol. 2007 Jun;34(6):1401-14. Erratum in: J Rheumatol. 2014 Nov;41(11):2336. Bingham, Clifton [corrected to Bingham, Clifton O 3rd].

PMID:
17552067
10.

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.

Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O.

Ann Rheum Dis. 2007 Jul;66(7):893-9. Epub 2007 Apr 5.

11.

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.

Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, Wagner C, Han J, Westhovens R.

Ann Rheum Dis. 2007 Sep;66(9):1233-8. Epub 2007 Mar 28.

12.

SLE in a United States-Mexico border community.

Walsh BT, Pope C, Reid M, Gall EP, Yocum DE, Clark LC.

J Clin Rheumatol. 2001 Feb;7(1):3-9.

PMID:
17039079
13.

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman MU; START Study Group.

Arthritis Rheum. 2006 Apr;54(4):1075-86. Erratum in: Arthritis Rheum. 2007 May;56(5):1675. Dosage error in article text.

14.

Response: office-based low-field extremity magnetic resonance imaging: is the glass half empty or half full?

Yocum DE, Conaghan PG, Olech E, Peterfy CG.

Arthritis Rheum. 2006 Apr;54(4):1048-50. No abstract available.

15.

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ.

N Engl J Med. 2006 Feb 23;354(8):795-808.

16.

Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis.

Mazzuca SA, Brandt KD, Schauwecker DS, Katz BP, Meyer JM, Lane KA, Bradley JD, Hugenberg ST, Wolfe F, Moreland LW, Heck LW, Yocum DE, Schnitzer TJ, Sharma L, Manzi S, Oddis CV.

J Rheumatol. 2005 Aug;32(8):1540-6.

PMID:
16078332
17.

Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial.

Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW.

Arthritis Rheum. 2005 Jul;52(7):2015-25.

18.

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE.

Semin Arthritis Rheum. 2005 Jun;34(6):819-36. Review.

PMID:
15942917
19.

Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug.

Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, Hugenberg ST, Manzi S, Moreland LW, Oddis CV, Schnitzer TJ, Sharma L, Wolfe F, Yocum DE.

Arthritis Rheum. 2004 Dec 15;51(6):933-40.

20.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.

Arthritis Rheum. 2004 Sep;50(9):2858-68.

21.

Effective use of TNF antagonists.

Yocum D.

Arthritis Res Ther. 2004;6 Suppl 2:S24-30. Epub 2004 Jun 21. Review.

22.

Does safety make a difference in selecting the right TNF antagonist?

Fleischmann R, Yocum D.

Arthritis Res Ther. 2004;6 Suppl 2:S12-8. Epub 2004 Jun 21. Review.

23.

Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.

Tang X, Yocum DE, Dejonghe D, Nordensson K, Lake DF, Richard J.

Immunology. 2004 Jul;112(3):496-505.

24.

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM.

Arthritis Rheum. 2004 Jun;50(6):1959-66.

25.

Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience.

Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisememandle W, Mekki QA; Tacrolimus RA Study Group.

Rheumatology (Oxford). 2004 Aug;43(8):992-9. Epub 2004 Mar 10.

PMID:
15014199
26.

Immune activation and depression in women with rheumatoid arthritis.

Zautra AJ, Yocum DC, Villanueva I, Smith B, Davis MC, Attrep J, Irwin M.

J Rheumatol. 2004 Mar;31(3):457-63.

PMID:
14994388
27.

Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.

Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA; Tcrolimus Rheumatoid Arthritis Study Group.

Arthritis Rheum. 2003 Dec;48(12):3328-37.

28.

The role of T-cells in rheumatoid arthritis and the use of immunomodulating drugs.

Yocum DE.

Drugs Today (Barc). 1999 Apr-May;35(4-5):295-307.

PMID:
12973434
29.

Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation.

Schluter SF, Adelman MK, Taneja V, David C, Yocum DE, Marchalonis JJ.

Cell Mol Biol (Noisy-le-grand). 2003 Mar;49(2):193-207.

PMID:
12887102
30.

Expression of PTHrP and its cognate receptor in the rheumatoid synovial microcirculation.

Funk JL, Wei H, Downey KJ, Yocum D, Benjamin JB, Carley W.

Biochem Biophys Res Commun. 2002 Oct 4;297(4):890-7.

PMID:
12359237
31.

Characterizing a soluble survival signal for activated lymphocytes from CD14+ cells.

Tang X, Yocum DE, DeJonghe D, Nordensson K.

Immunology. 2002 Sep;107(1):56-68.

32.

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.

Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.

Arthritis Rheum. 2002 Aug;46(8):2020-8.

33.

Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.

Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE.

Arthritis Rheum. 2002 Jun;46(6):1460-9.

34.

Human monoclonal natural autoantibodies against the T-cell receptor inhibit interleukin-2 production in murine T cells.

Robey IF, Schluter SF, Akporiaye E, Yocum DE, Marchalonis JJ.

Immunology. 2002 Apr;105(4):419-29.

35.

Specificity mapping of human anti-T cell receptor monoclonal natural antibodies: defining the properties of epitope recognition promiscuity.

Robey IF, Edmundson AB, Schluter SF, Yocum DE, Marchalonis JJ.

FASEB J. 2002 May;16(7):642-52.

PMID:
11978728
36.

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.

Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J.

J Rheumatol. 2002 Feb;29(2):220-9.

PMID:
11838838
37.

Combination therapy: the risks of infection and tumor induction.

Yocum DE.

Springer Semin Immunopathol. 2001;23(1-2):63-72. Review.

PMID:
11455862
38.
39.

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D.

Am J Ophthalmol. 2000 Oct;130(4):492-513. Review.

PMID:
11024423
40.

New and future drug therapies for rheumatoid arthritis.

Simon LS, Yocum D.

Rheumatology (Oxford). 2000 Jun;39 Suppl 1:36-42. Review.

PMID:
11001378
41.

Treatment of rheumatoid arthritis with a DR4/1 peptide.

St Clair EW, Cohen SB, Lee ML, Fleischmann RM, Lee SH, Moreland LW, Olsen NJ, Pratt PW, Yocum DE, Heck L, Winkelhake J, Holcenberg JS, Shulman MJ.

J Rheumatol. 2000 Aug;27(8):1855-63.

PMID:
10955324
42.

Production and characterization of monoclonal IgM autoantibodies specific for the T-cell receptor.

Robey IF, Schluter SF, Yocum DE, Marchalonis JJ.

J Protein Chem. 2000 Jan;19(1):9-21.

PMID:
10882168
43.

Epitope promiscuity of human monoclonal autoantibodies to T-cell receptor-combining site determinants.

Marchalonis JJ, Robey I, Schluter SF, Yocum DE.

Appl Biochem Biotechnol. 2000 Jan-Mar;83(1-3):31-49; discussion 49-52, 145-53.

PMID:
10826947
44.

Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.

Yocum DE, Allard S, Cohen SB, Emery P, Flipo RM, Goobar J, Jayawardena S, Job-Deslandre C, Jubb RW, Kr├╝ger K, Lopes Vaz A, Manger B, Mur E, Nygaard H, Weiner SM, Rainer F, Sack MR, Schiff MH, Schnitzer TJ, Trigg LB, Whatmough I, Schmidt AG.

Rheumatology (Oxford). 2000 Feb;39(2):156-64.

PMID:
10725065
45.

Exercise, education, and behavioral modification as alternative therapy for pain and stress in rheumatic disease.

Yocum DE, Castro WL, Cornett M.

Rheum Dis Clin North Am. 2000 Feb;26(1):145-59, x-xi. Review.

PMID:
10680202
46.

T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis.

Yocum DE.

Semin Arthritis Rheum. 1999 Aug;29(1):27-35. Review.

PMID:
10468412
47.

US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis.

Cush JJ, Tugwell P, Weinblatt M, Yocum D.

J Rheumatol. 1999 May;26(5):1176-86.

PMID:
10332987
48.

Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.

Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D.

Arthritis Rheum. 1999 Feb;42(2):357-65.

49.

Glucocorticosteroids in rheumatoid arthritis: lessons for the future.

Yocum DE.

Br J Rheumatol. 1998 Nov;37(11):1145-7. No abstract available.

PMID:
9851258
50.

An examination of individual differences in the relationship between interpersonal stress and disease activity among women with rheumatoid arthritis.

Zautra AJ, Hoffman JM, Matt KS, Yocum D, Potter PT, Castro WL, Roth S.

Arthritis Care Res. 1998 Aug;11(4):271-9.

PMID:
9791326

Supplemental Content

Support Center